Funding for this research was provided by:
National Breast Cancer Foundation (PF-17-007)
Cancer Council SA’s Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health (XXXXXX)
Received: 11 December 2019
Accepted: 20 February 2020
First Online: 27 February 2020
Ethics approval and consent to participate
: Secondary analysis of participant-level data for the BRIM-2, BRIM-3 and coBRIM clinical studies was approved by the Southern Adelaide Clinical Human Research Ethics Committee (SAC HREC EC00188) and accessed according to Roche’s policy and process for clinical study data sharing [CitationRef removed].The trials conducted by Roche were performed in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. Protocol approval was obtained from an independent ethics committee at each study site. All patients provided written informed consent [CitationRef removed, CitationRef removed, CitationRef removed].
: Not applicable.
: Dr. Sorich and Dr. Rowland report grants from Pfizer, outside the submitted work. No potential conflicts of interest were reported by the other authors.